Drugs / PD-L1 t-haNK
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04050709 | Jul 2019 → Mar 2021 | metastatic malignant neoplasm | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06061809 | Aug 2024 → Dec 2029 expected | glioblastoma | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06239220 | Feb 2024 → Jul 2026 overdue | head and neck squamous cell carcinoma | Glenn J. Hanna | Recruiting | No outcome recorded |
| Phase 2 | NCT04847466 | Dec 2021 → Dec 2025 | gastroesophageal cancer, head and neck squamous cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04390399 | Jul 2020 → Oct 2025 overdue | malignant pancreatic neoplasm | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03228667 | Dec 2018 → Aug 2029 expected | cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma, gastric cancer +8 | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04927884 Background | Sep 2021 → Sep 2022 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-L1 t-haNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04847466 ↗ |
| Action | Deplete | “highly effective at lysing PD-L1 expressing tumor cells” NCT04847466 ↗ |
| Modality | Cell therapy | “off the shelf, irradiated human, allogeneic, NK cell line” NCT04847466 ↗ |
| Route | Intravenous | “PD-L1 t-haNK administered IV” NCT03228667 ↗ |